Alaunos Therapeutics, Inc.
TCRT
$3.59
$0.030.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.83% | 79.13% | 84.80% | 86.68% | 67.69% |
| Total Depreciation and Amortization | -100.41% | -100.11% | -100.00% | -99.91% | -91.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -79.80% | -91.68% | -95.09% | -94.27% | -11.60% |
| Change in Net Operating Assets | 112.84% | 115.69% | 98.31% | 88.34% | -118.77% |
| Cash from Operations | 75.27% | 83.60% | 83.13% | 83.51% | 60.64% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 2,285.71% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -106.45% | -- | -- | -- | 701.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 99.49% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -- | -- | -- | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.49% | 102.62% | 88.51% | 89.41% | 74.22% |